Metastatic renal carcinoma comprehensive prognostic system

British Journal of Cancer

Volumn 88, Issue 3, 2003, Pages 348-353

  Atzpodien, J ^a,b,c   Royston, P ^d   Wandert, T ^c   Reitz, M ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c Europaisches Institut fur Tumor Immunologie und Pravention   (Germany)

^d MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

Immunotherapy; Prognosis; Renal cell carcinoma; Risk; Stratification; Survival

Indexed keywords

ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; FLUOROURACIL; INTERLEUKIN 2; ISOTRETINOIN; LACTATE DEHYDROGENASE;

ADULT; ARTICLE; BLOOD CELL COUNT; BONE METASTASIS; BRAIN METASTASIS; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER MODEL; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; ENZYME BLOOD LEVEL; FEMALE; HIGH RISK PATIENT; HUMAN; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; METASTASIS; NEUTROPHIL; OUTPATIENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME;

CARCINOMA, RENAL CELL; FEMALE; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0037428774     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600768     Document Type: Article

References (20)

1. Altman DG, Lausen B, Sauerbrei W (1994) Danger of using 'optimal' cutpoints in the evaluation of prognostic factors. J Nat Cancer Inst 86(11): 829-835
2. Atzpodien J, Kirchner H, Illiger HJ, Metzner B, Ukena D, Schott H, Funke PJ, Gramatzki M, von Jürgenson S, Wandert T, Patzelt T, Reitz M. (2001) IL-2 in combination with IFN-α and 5-FU versus tamoxifen in metastatic renal-cell carcinoma: long-term results of a controlled randomised clinical trial. Br J Cancer 85(8): 1130-1136
3. Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornaia P, Loening SA, Roigas J, Müller SC, Westerhausen H, Helbig W, Bodenstein H, Pomer S, Metzner B, Rebmann U, Hofstetter A, Oberneder R, Siebels TI, Wandert T, Patzelt T, Reitz M, DGCIN-Group (2002) 13-CIS-retinoic acid, IFN-alpha2a, IL-2 and chemotherapy in advanced renalcell carcinoma: results of a prospectively randomized trial of The German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol (submitted).
4. Atzpodien J, Korfer A, Franks CR, Knuver-Hopf J, Lopez-Hanninen E, Fischer M, Mohr H, Dallmann I, Hadam M. (1990) Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet; 335: 1509-1512
5. Blay JY, Rossi JF, Wijdenes J, Menetrier-Caux C, Schemann S, Negrier S, Philip T, Favrot M (1997) Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer: 72(3): 424-430
6. Culine S, Bekradda M, Kramar A, Rey A, Escudier B, Droz JP (1998) Prognostic factors for survival in patients with brain metastases from renal-cell carcinoma. Cancer 83(12): 2548-2553
7. Elson PJ, Witte RS, Trump DL (1988) Prognostic factors for survival in patients with recurrent or metastatic renal-cell carcinoma. Cancer Res 48(24 Pt 1): 7310-7313
8. Gelb AB. (1997) Renal cell carcinoma: current prognostic factors. Union Internationale Contre le Cancer (UIC) and American Joint Committee on Cancer (AJCC). Cancer 80(5): 981-986
9. Hoffmann R, Franzke A, Buer J, Sel S, Oevermann K, Duensing A, Probst M, Duensing S, Kirchner H, Ganser A, Atzpodien J (1999) Prognostic impact of invivo soluble cell adhesion molecules in metastatic renal cell carcinoma. Br J Cancer 79(11-12): 1742-1745
10. Kapp DS, Fischer D, Gutierrez E, Kohorn EI, Schwartz PE. (1983) Pretreatment prognostic factors in carcinoma of the uterine cervix: a multivariable analysis of the effect of age, stage, histology and blood counts on survival. Int J Radiat Oncol Biol Phys 9(4): 445-455
11. Lopez-Hänninen E, Kirchner H, Atzpodien J (1996) Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 155: 19-25
12. Maldazys JD, deKernion JB (1986) Prognostic factors in metastatic renal carcinoma. J Urol 136(2): 376-379
13. Mani S, Todd MB, Katz K, Poo WJ (1995) Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 154(1): 35-40
14. Miller R, Siegmund D (1982) Maximally selected chi-square statistics. Biometrics 38: 1011-1016
15. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies aganst advanced renal cell carcinoma. J Clin Oncol 20(1): 289-296
16. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal-cell carcinoma. J Clin Oncol 17(8): 2530-2540
17. Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R, Bureau G, Dabouis G, Van Cutsem O, Mommen P, Ninane V, Klastersky J (2000) Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 89(3): 523-533
18. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Sergysels R, Mommen P et al (1995) Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analysis including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 13(5): 1221-1230
19. Palmer PA, Vinke J, Philip T, Negrier S, Atzpodien J, Kirchner H, Oskam R, Francs CR (1992) Prognostic factors for survival in patients with advanced renal-cell carcinoma treated with recombined inerleukin-2. Ann Oncol 3(6): 475-480
20. Sleijfer DT, Janssen RA, Buter J, de Vries EG, Willemse PH, Mulder NH (1992) Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal-cell cancer on an outpatient basis. J Clin Oncol 10(7): 1119-1123